Classification and Chemical Structure
Pipecuronium bromide (Pipecuronium bromid) is a classical representative of nondepolarizing neuromuscular blockers. In pharmacology, drugs of this group are divided into two main classes based on their chemical structure.
Pipecuronium belongs to aminosteroids because its molecular backbone is based on a steroid nucleus. Other members of this chemical subgroup include pancuronium bromide, vecuronium bromide, and rocuronium bromide.
The second major group is benzylisoquinolines, which are structurally characterized by the presence of isoquinoline rings. These include the historical prototype tubocurarine, as well as atracurium besilate, cisatracurium besilate, and mivacurium chloride.
Duration of Action
Depending on the duration of the induced neuromuscular block, muscle relaxants are divided into three groups. Pipecuronium bromide is classified as a long-acting agent (lasting 30–60 minutes or more).
Furthermore, among all curare-like drugs in clinical use, pipecuronium exhibits the longest duration of effect, reaching up to about 2 hours. The long-acting group also includes tubocurarine and pancuronium.
For comparison, if shorter muscle relaxation is required, intermediate-acting agents (20–40 minutes, e.g., atracurium, vecuronium, rocuronium) or short-acting agents (10–15 minutes, mivacurium) are used.
Pharmacokinetics and Elimination Pathways
The duration of effect of curare-like agents directly depends on their elimination or degradation pathway in the body. Pipecuronium is excreted primarily by the kidneys. This specific elimination pathway accounts for its prolonged duration of action.
Elimination pathways of other groups:
- Biliary excretion (unchanged or as metabolites) — vecuronium, rocuronium.
- Hoffmann elimination (spontaneous non-enzymatic plasma hydrolysis) — atracurium.
- Degradation by plasma cholinesterase (pseudocholinesterase) — mivacurium.
Formulation and Administration
Pipecuronium bromide is available as a powder in 0.004 g vials (supplied with a matching solvent).
The drug is administered strictly intravenously. Dosage calculation is individualized and ranges from 70 to 80 mcg/kg of body weight.
Clinical Considerations
Because pipecuronium is eliminated renally, its use requires special caution in patients with impaired renal function.
In cases of renal or hepatic impairment, atracurium besilate becomes the drug of choice. Thanks to Hoffmann elimination, the duration of action of atracurium is entirely independent of liver and kidney function, making its use safer and more predictable in this patient population.